참고문헌 (57)

1. Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3-21. 

   상세보기

2. Robins LN, Regier DA. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991. 

3. Cho MJ, Chang SM, Hahm BJ, Chung IW, Bae A, Lee YM, et al. Prevalence and correlates of major mental disorders among Korean adults: a 2006 National Epidemiologic Survey. J Korean Neuropsychiatr Assoc 2009;48:143-152. 

4. Korean Neuropsychiatric Association. Textbook of Neuropsychiatry. 3rd ed. Seoul: iMiS Company;2017. 

5. Song HR, LEE HY, Shim SH, Kwon YJ. Neuroinflammation and psychiatric illness. Korean J Biol Psychiatry 2016;23:12-17. 

6. Leonard BE. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:261-267. 

7. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015;23:1-21. 

   상세보기

8. Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 2015;20:1142-1150. 

   상세보기

9. Weilburg JB. An overview of SSRI and SNRI therapies for depression. Manag Care 2004;13:25-33. 

   상세보기

10. Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011;12:1623-1632. 

    상세보기

11. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62 Suppl 18:4-11. 

12. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-659. 

    상세보기

13. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163:210-216. 

14. Bahk WM, Min KJ. Textbook of depressive disorders. Seoul: Sigma press;2012. 

15. Jeong HJ, Moon E. Novel pharmacological treatment for depression. Korean J Biol Psychiatry 2016;23:1-11 

16. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61Suppl 11:37-41. 

17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA: American Psychaitric Association;2013. 

18. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012;35:1171-1180. 

    상세보기

19. Cho SJ, Lee HJ, Rhee SJ, Kim EY, Kim KN, Yoon DH, et al. The relationship between visceral adiposity and depressive symptoms in the general Korean population. J Affect Disord 2019;244:54-59. 

20. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, National Heart L, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13-e18. 

    상세보기

21. Assari S, Caldwell CH. Gender and Ethnic Differences in the association between obesity and depression among black adolescents. J Racial Ethn Health Disparities 2015;2:481-493. 

    상세보기

22. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, doubleblind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991;24:62-67. 

    상세보기

23. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999;156:1170-1176. 

24. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21:643-658. 

    상세보기

25. Moon CA, Jesinger DK. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Br J Clin Pract 1991;45:259-262. 

    상세보기

26. Shi Z, Atlantis E, Taylor AW, Gill TK, Price K, Appleton S, et al. SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles: results from a 4-year Australian follow-up study. BMJ Open 2017;7:e016224. 

    상세보기

27. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000;61:863-867. 

    상세보기

28. Aberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000;20:645-652. 

    상세보기

29. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999;60:22-28. 

30. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ 2018;361:k1951. 

    상세보기

31. Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52- week extension study. Int Clin Psychopharmacol 2014;29:36-44. 

    상세보기

32. Tourian KA, Leurent C, Graepel J, Ninan PT. Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry 2010;12:e1-e8. 

    상세보기

33. Harto-Truax N, Stern WC, Miller LL, Sato TL, Cato AE. Effects of bupropion on body weight. J Clin Psychiatry 1983;44:183-186. 

34. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-196. 

35. Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Kim YW, et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:208-211. 

36. Lee J, Cho SJ, Lee KS, Yook K, Choe AY, Lee S, et al. The tolerability of mirtazapine augmentation in schizophrenic patients treated with risperidone: a preliminary randomized placebo-controlled Trial. Clin Psychopharmacol Neurosci 2011;9:73-77. 

    상세보기

37. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998;13:63-73. 

    상세보기

38. Goodnick PJ, Kremer C, Wingard P. Weight change during mirtazapine therapy. Prim Psychiatry 1998;3:103-108. 

39. Caffey EM Jr, Rosenblum MP, Klett CJ. Side effects and laboratory findings in a study of anti-depressant drugs. Dis Nerv Syst 1962;23:444-449. 

40. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988;26:265-271. 

    상세보기

41. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988;8:323-330. 

42. Frank E, Kupfer DJ, Bulik CM, Levenson JA. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 1990;20:165-172. 

43. Frank E, Kupfer DJ, Buhari A, McEachran AB, Grochocinski VJ. Imipramine and weight gain during the long-term treatment of recurrent depression. J Affect Disord 1992;26:65-72. 

44. Feiger AD, Bielski RJ, Bremner J, Heiser JF, Trivedi M, Wilcox CS, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999;14:19-28. 

    상세보기

45. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight. Psychiatr Ann 1999;29:580-594. 

    상세보기

46. Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013:CD008851. 

47. Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord 1984;7:133-138. 

48. Benazzi F. Weight gain in depression remitted with antidepressants: pharmacological or recovery effect? Psychother Psychosom 1998;67:271-274. 

    상세보기

49. Fernstrom MH, Kupfer DJ. Imipramine treatment and preference for sweets. Appetite 1988;10:149-155. 

    상세보기

50. Levitt AJ, Joffe RT, Esche I, Sherret D. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987;48:27-28. 

51. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996;11:273-278. 

    상세보기

52. Wright DE, Seroogy KB, Lundgren KH, Davis BM, Jennes L. Comparative localization of serotonin 1A , 1C , and 2 receptor subtype mRNAs in rat brain. J Comp Neurol 1995;351:357-373. 

53. Hoffman BJ, Mezey E. Distribution of serotonin 5-HT 1C receptor mRNA in adult rat brain. FEBS Lett 1989;247:453-462. 

    상세보기

54. Britton DR, Koob GF, Rivier J, Vale W. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci 1982;31:363-367. 

    상세보기

55. Levine AS, Rogers B, Kneip J, Grace M, Morley JE. Effect of centrally administered corticotropin releasing factor (CRF) on multiple feeding paradigms. Neuropharmacology 1983;22:337-339. 

    상세보기

56. Pijl H, Koppeschaar HP, Willekens FL, Op de Kamp I, Veldhuis HD, Meinders AE. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 1991;15:237-242. 

    상세보기

57. Fernstrom MH. Depression, antidepressants, and body weight change. Ann N Y Acad Sci 1989;575:31-39.